Jumpcan 济川药业
22 significant filings since 30 May 2026: 14 on buyback, 4 on equity incentive and 2 on major holder selling, and 1 other kind. The latest, on 25 Sep 2026: 国浩律师(上海)事务所关于济川药业2022 年限制性股票与股票期权激励计划首次授予部分第二个解除限售期解除限售条件及第二个行权期行权条件成就并注销部分股票期权及回购注销部分限制性股票事项之法律意见书.
自 30 May 2026 起有 22 份重大公告：buyback 14 份、equity incentive 4 份、major holder selling 2 份，另有 1 类。最新一份（25 Sep 2026）：国浩律师(上海)事务所关于济川药业2022 年限制性股票与股票期权激励计划首次授予部分第二个解除限售期解除限售条件及第二个行权期行权条件成就并注销部分股票期权及回购注销部分限制性股票事项之法律意见书。
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥225亿 | ¥61亿 | 9th highest of 66 · 66 家中第 9 高 | |
| Trailing P/E 市盈率 | 12.2x | 31.3x | 3rd lowest of 49 · 49 家中第 3 低 | |
| P/B 市净率 | 1.6x | 2.2x | 22nd lowest of 65 · 65 家中第 22 低 | |
| Revenue Growth 营收增速 | -15.3% | -7.4% | 21st lowest of 66 · 66 家中第 21 低 | |
| Profit Growth 净利增速 | 8.3% | -0.2% | 22nd highest of 66 · 66 家中第 22 高 | |
| Gross Margin 毛利率 | 79.5% | 56.9% | 3rd highest of 66 · 66 家中第 3 高 | |
| Net Margin 净利率 | 33.6% | 9.6% | 3rd highest of 66 · 66 家中第 3 高 | |
| Return on Equity 净资产收益率 | 5.3% | 3.0% | 23rd highest of 65 · 65 家中第 23 高 | |
| Debt to Assets 资产负债率 | 18.8% | 28.4% | 16th lowest of 66 · 66 家中第 16 低 | |
| Grade Score 评级得分 | 67 | 52 | 12th highest of 66 · 66 家中第 12 高 |
Statement figures are for the period to 30 Jun 2026, filed by 66 of 66 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，66 家同业中 66 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Yunnan Baiyao Group 云南白药 | ¥890亿 | 17.0x | 2.2x | 2.9% | 16.9% | 9.0% | C |
| Zhangzhou Pientzehuang Pharmaceutical 片仔癀 | ¥708亿 | 39.1x | 4.8x | -15.0% | 23.7% | 7.3% | C |
| China Resources Sanjiu Medical 华润三九 | ¥389亿 | 11.9x | 1.7x | 1.4% | 13.3% | 7.3% | C |
| Beijing Tong Ren Tang 同仁堂 | ¥320亿 | 33.0x | 2.3x | -14.2% | 11.2% | 5.2% | D |
| Guangzhou Baiyunshan Pharmaceutical Holdings 白云山 | ¥315亿 | 12.3x | 0.8x | 0.6% | 5.1% | 5.4% | D |
| Dong-E-E-Jiao 东阿阿胶 | ¥289亿 | 16.2x | 2.8x | 3.4% | 27.3% | 8.1% | C |
| Tianjin Pharmaceutical Da Ren Tang 达仁堂 | ¥271亿 | 31.9x | 4.6x | -7.4% | 26.2% | 9.1% | C |
| Shijiazhuang Yiling Pharmaceutical 以岭药业 | ¥253亿 | 18.4x | 2.3x | 0.9% | 18.6% | 6.7% | B |
| Jumpcan 济川药业 | ¥225亿 | 12.2x | 1.6x | -15.3% | 33.6% | 5.3% | C |
| Jilin Aodong Pharmaceutical Group 吉林敖东 | ¥209亿 | 6.6x | 0.7x | -8.5% | 198.7% | 6.5% | C |
| Tasly 天士力 | ¥204亿 | 16.7x | 1.6x | -2.0% | 21.1% | 7.0% | C |
| Guangdong Zhongsheng Pharmaceutical 众生药业 | ¥198亿 | 99.6x | 5.0x | -23.0% | 10.7% | 2.7% | C |
| Kangmei Pharmaceutical 康美药业 | ¥184亿 | 624.3x | 2.5x | -11.1% | 1.6% | 0.5% | D |
| Buchang Pharma 步长制药 | ¥153亿 | 65.0x | 1.5x | -11.7% | 9.2% | 4.9% | D |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。